By continuing browsing this website, you accept the use of cookies
to help us improve your user experience.

I agree
Loading... (0%)
About liver disease
GENFIT is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions to address high unmet patient needs...
Learn more
Elafibranor phase 3 study in NASH with fibrosis is currently recruiting patients all around the world.

Press releases
  • GENFIT: The NASH Education Program announces the launch of the first International NASH Information Day on June 12, 2018: Save the date!
  • GENFIT Reaches a Critical Milestone towards the Development of a Non-Invasive In Vitro Diagnostic (IVD) Test for NASH
  • GENFIT: Positive Outcome from the 1-year Pre-Planned Safety Review by the DSMB, in RESOLVE-IT Phase 3 Clinical Trial with Elafibranor
  • GENFIT: First Patient enrolled in a Phase 2 Trial recruiting Adults with Primary Biliary Cholangitis (PBC), a Rare Liver Disease